- NR and NAD+ gaining more attention as consumers continue to look for ways to rejuvenate their energy
IRVINE, Calif., Sept. 22, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness
and nutritional ingredients that creates science-based solutions to dietary supplement, food and beverage, skin care, sports
nutrition, and pharmaceutical products, announced leading supplement retailer, Vitamin Shoppe, featured NIAGEN®
nicotinamide riboside (NR) in their Hot Ingredient Spotlight section in the Fall 2016 print edition of their Amazing Wellness magazine.
ChromaDex founder and CEO, Frank Jaksch, Jr. commented, “As the aging population continues to grow, their interest in what can
be done to rediscover that sense of vitality or youthful energy grows. The scientific evidence validating NR’s ability to increase
cellular NAD+, has people interested and wanting to learn more.” Jaksch continued, “This type of coverage is a perfect
complement to the ongoing consumer outreach we are doing to help people understand that the answer lies within their own
cells.”
About ChromaDex:
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary
ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to
our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as
"phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix
Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and
license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting
business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific
research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a
spirulina extract; and AnthOrigin™, anthocyanins derived from a domestically-produced, water-extracted purple corn. To learn more
about ChromaDex, please visit www.ChromaDex.com.
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical
facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should",
"could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors
that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal
year ended January 2, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies
of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date
hereof.
ChromaDex Public Relations Contact: Breah Ostendorf, Director of Marketing 949-537-4103 breaho@chromadex.com ChromaDex Investor Relations Contact: Andrew Johnson, Director of Investor Relations 949-419-0288 andrewj@chromadex.com